VBI Vaccines initiated with an Outperform at Oppenheimer. Oppenheimer analyst Leland Gershell started VBI Vaccines with an Outperform rating and 12- to 18-month price target of $9. The company is advancing three candidates through clinical development for infection prevention and cancer treatment, Gershell tells investors in a research note. The analyst believes positive newsflow from any of the programs “could spark share appreciation.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.